Rob Oslund is InduPro’s Vice President of Platform Technology leading chemical biology and proximity labeling platform technology functions at the Company.
Prior to joining InduPro, Rob was a founding member of the Merck Exploratory Science Center co-leading a cellular chemistry team focused on developing novel platform technologies to enable therapeutic development. He co-invented photocatalytic-based proximity labeling and led efforts to profile surface protein environments and explore cell-cell interaction biology. Also while at Merck, Rob developed novel covalent labeling technologies for target identification and was involved in multiple modality agnostic drug discovery programs. Rob is a co-founder of the STEM Hub for Industry Networking and Exchange (S.H.I.N.E.) program for underrepresented STEM students with over 400 mentee/mentor pairs participating across 25 biotech/pharma companies.
Prior to Merck, Rob was a peptide chemist and biochemist at Neon Therapeutics (now BioNTech) developing high throughput peptide synthesis platforms and proteomic workflows to investigate HLA peptide ligandomes for cancer vaccine development.
Rob did his postdoc in the lab of Tom Muir at Princeton University where he developed a pan-specific antibody to phosphorylated histidine and applied this to biological systems to investigate the role of bisphosphoglycerate mutase in serine pathway flux. Rob earned his PhD from the University of Washington in Seattle with Professor Mike Gelb where he studied phospholipase enzymes through design and synthesis of selective phospholipase small molecule inhibitors. Rob received his B.S. in Chemistry from Southern Utah University in Cedar City, Utah. He is originally from Henderson, NV.